PURPOSE: Technologic advances have led to increased clinical use of higher-sized fractions of radiation dose and higher total doses. How these modify the pathways involved in tumor cell death, normal tissue response, and signaling to the immune system has been inadequately explored. Here we ask how radiation dose and fraction size affect antitumor immunity, the suppression thereof, and how this might relate to tumor control. METHODS AND MATERIALS: Mice bearing B16-OVA murine melanoma were treated with up to 15 Gy radiation given in various-size fractions, and tumor growth followed. The tumor-specific immune response in the spleen was assessed by interferon-γ enzyme-linked immunospot (ELISPOT) assay with ovalbumin (OVA) as the surrogate tumor antigen and the contribution of regulatory T cells (Tregs) determined by the proportion of CD4(+)CD25(hi)Foxp3(+) T cells. RESULTS: After single doses, tumor control increased with the size of radiation dose, as did the number of tumor-reactive T cells. This was offset at the highest dose by an increase in Treg representation. Fractionated treatment with medium-size radiation doses of 7.5 Gy/fraction gave the best tumor control and tumor immunity while maintaining low Treg numbers. CONCLUSIONS: Radiation can be an immune adjuvant, but the response varies with the size of dose per fraction. The ultimate challenge is to optimally integrate cancer immunotherapy into radiation therapy.
PURPOSE: Technologic advances have led to increased clinical use of higher-sized fractions of radiation dose and higher total doses. How these modify the pathways involved in tumor cell death, normal tissue response, and signaling to the immune system has been inadequately explored. Here we ask how radiation dose and fraction size affect antitumor immunity, the suppression thereof, and how this might relate to tumor control. METHODS AND MATERIALS: Mice bearing B16-OVAmurinemelanoma were treated with up to 15 Gy radiation given in various-size fractions, and tumor growth followed. The tumor-specific immune response in the spleen was assessed by interferon-γ enzyme-linked immunospot (ELISPOT) assay with ovalbumin (OVA) as the surrogate tumor antigen and the contribution of regulatory T cells (Tregs) determined by the proportion of CD4(+)CD25(hi)Foxp3(+) T cells. RESULTS: After single doses, tumor control increased with the size of radiation dose, as did the number of tumor-reactive T cells. This was offset at the highest dose by an increase in Treg representation. Fractionated treatment with medium-size radiation doses of 7.5 Gy/fraction gave the best tumor control and tumor immunity while maintaining low Treg numbers. CONCLUSIONS: Radiation can be an immune adjuvant, but the response varies with the size of dose per fraction. The ultimate challenge is to optimally integrate cancer immunotherapy into radiation therapy.
Authors: Evelyn L Kachikwu; Keisuke S Iwamoto; Yu-Pei Liao; John J DeMarco; Nzhde Agazaryan; James S Economou; William H McBride; Dörthe Schaue Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-17 Impact factor: 7.038
Authors: M Bellone; D Cantarella; P Castiglioni; M C Crosti; A Ronchetti; M Moro; M P Garancini; G Casorati; P Dellabona Journal: J Immunol Date: 2000-09-01 Impact factor: 5.422
Authors: Amit A Lugade; Elizabeth W Sorensen; Scott A Gerber; James P Moran; John G Frelinger; Edith M Lord Journal: J Immunol Date: 2008-03-01 Impact factor: 5.422
Authors: William H McBride; Chi-Shiun Chiang; Jennifer L Olson; Chun-Chieh Wang; Ji-Hong Hong; Frank Pajonk; Graeme J Dougherty; Keisuke S Iwamoto; Milena Pervan; Yu-Pei Liao Journal: Radiat Res Date: 2004-07 Impact factor: 2.841
Authors: Nils-Petter Rudqvist; Karsten A Pilones; Claire Lhuillier; Erik Wennerberg; John-William Sidhom; Ryan O Emerson; Harlan S Robins; Jonathan Schneck; Silvia C Formenti; Sandra Demaria Journal: Cancer Immunol Res Date: 2017-11-27 Impact factor: 11.151
Authors: Megan Morisada; Paul E Clavijo; Ellen Moore; Lillian Sun; Michael Chamberlin; Carter Van Waes; James W Hodge; James B Mitchell; Jay Friedman; Clint T Allen Journal: Oncoimmunology Date: 2017-11-27 Impact factor: 8.110
Authors: E Liniker; A M Menzies; B Y Kong; A Cooper; S Ramanujam; S Lo; R F Kefford; G B Fogarty; A Guminski; T W Wang; M S Carlino; A Hong; G V Long Journal: Oncoimmunology Date: 2016-08-19 Impact factor: 8.110
Authors: Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan Journal: Oncoimmunology Date: 2018-03-15 Impact factor: 8.110